HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes
HER2 is an emerging biomarker in colorectal cancer (CRC). This oncogene plays an essential role in regulating cell proliferation, differentiation, migration, and, more in general, tumorigenesis and tumor progression. The most frequent types of HER2 alterations in CRC include gene amplification and m...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/9/1403 |
| _version_ | 1827659461832998912 |
|---|---|
| author | Mariia Ivanova Konstantinos Venetis Elena Guerini-Rocco Luca Bottiglieri Mauro Giuseppe Mastropasqua Ornella Garrone Nicola Fusco Michele Ghidini |
| author_facet | Mariia Ivanova Konstantinos Venetis Elena Guerini-Rocco Luca Bottiglieri Mauro Giuseppe Mastropasqua Ornella Garrone Nicola Fusco Michele Ghidini |
| author_sort | Mariia Ivanova |
| collection | DOAJ |
| description | HER2 is an emerging biomarker in colorectal cancer (CRC). This oncogene plays an essential role in regulating cell proliferation, differentiation, migration, and, more in general, tumorigenesis and tumor progression. The most frequent types of HER2 alterations in CRC include gene amplification and missense mutations in 7–8% of CRC, often being mirrored by HER2 protein overexpression, representing founder events in solid tumors, including CRC. There are currently no approved HER2-targeted therapy guidelines for CRC; however, several studies have shown that HER2 can be effectively targeted in meta-static CRC settings. In this review, we discuss the current knowledge of HER2 testing in CRC and the immediate future perspectives for HER2 targeting in the metastatic setting. |
| first_indexed | 2024-03-09T23:22:46Z |
| format | Article |
| id | doaj.art-b9afc787e5b64098ba3c616df0adb36c |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T23:22:46Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-b9afc787e5b64098ba3c616df0adb36c2023-11-23T17:23:30ZengMDPI AGLife2075-17292022-09-01129140310.3390/life12091403HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic SchemesMariia Ivanova0Konstantinos Venetis1Elena Guerini-Rocco2Luca Bottiglieri3Mauro Giuseppe Mastropasqua4Ornella Garrone5Nicola Fusco6Michele Ghidini7Division of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, Via Giuseppe Ripamonti 435, 20141 Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, Via Giuseppe Ripamonti 435, 20141 Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, Via Giuseppe Ripamonti 435, 20141 Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, Via Giuseppe Ripamonti 435, 20141 Milan, ItalyDepartment of Emergency and Organ Transplantation, School of Medicine, University of Bari “Aldo Moro”, Piazza G Cesare, 11, 70124 Bari, ItalyMedical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, ItalyDivision of Pathology, IEO, European Institute of Oncology IRCCS, University of Milan, Via Giuseppe Ripamonti 435, 20141 Milan, ItalyMedical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, ItalyHER2 is an emerging biomarker in colorectal cancer (CRC). This oncogene plays an essential role in regulating cell proliferation, differentiation, migration, and, more in general, tumorigenesis and tumor progression. The most frequent types of HER2 alterations in CRC include gene amplification and missense mutations in 7–8% of CRC, often being mirrored by HER2 protein overexpression, representing founder events in solid tumors, including CRC. There are currently no approved HER2-targeted therapy guidelines for CRC; however, several studies have shown that HER2 can be effectively targeted in meta-static CRC settings. In this review, we discuss the current knowledge of HER2 testing in CRC and the immediate future perspectives for HER2 targeting in the metastatic setting.https://www.mdpi.com/2075-1729/12/9/1403HER2colorectal cancerpathologybiomarkerstargeted therapy |
| spellingShingle | Mariia Ivanova Konstantinos Venetis Elena Guerini-Rocco Luca Bottiglieri Mauro Giuseppe Mastropasqua Ornella Garrone Nicola Fusco Michele Ghidini HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes Life HER2 colorectal cancer pathology biomarkers targeted therapy |
| title | HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes |
| title_full | HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes |
| title_fullStr | HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes |
| title_full_unstemmed | HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes |
| title_short | HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes |
| title_sort | her2 in metastatic colorectal cancer pathology somatic alterations and perspectives for novel therapeutic schemes |
| topic | HER2 colorectal cancer pathology biomarkers targeted therapy |
| url | https://www.mdpi.com/2075-1729/12/9/1403 |
| work_keys_str_mv | AT mariiaivanova her2inmetastaticcolorectalcancerpathologysomaticalterationsandperspectivesfornoveltherapeuticschemes AT konstantinosvenetis her2inmetastaticcolorectalcancerpathologysomaticalterationsandperspectivesfornoveltherapeuticschemes AT elenaguerinirocco her2inmetastaticcolorectalcancerpathologysomaticalterationsandperspectivesfornoveltherapeuticschemes AT lucabottiglieri her2inmetastaticcolorectalcancerpathologysomaticalterationsandperspectivesfornoveltherapeuticschemes AT maurogiuseppemastropasqua her2inmetastaticcolorectalcancerpathologysomaticalterationsandperspectivesfornoveltherapeuticschemes AT ornellagarrone her2inmetastaticcolorectalcancerpathologysomaticalterationsandperspectivesfornoveltherapeuticschemes AT nicolafusco her2inmetastaticcolorectalcancerpathologysomaticalterationsandperspectivesfornoveltherapeuticschemes AT micheleghidini her2inmetastaticcolorectalcancerpathologysomaticalterationsandperspectivesfornoveltherapeuticschemes |